Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug; Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve

Taking stock of the drug industry, from the lab to the medicine chest

October 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark J. Terrill/AP STAT+ | Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug Public Citizen argues that Amgen patent tactics will have added nearly $2 billion to Medicare spending for the drug by 2026. By Ed Silverman STAT+ | Eli Lilly to pay $200 million for Beam's share of drugs from gene-editing firm Verve The deal also provides Beam, which announced on Oct. 19 that it would cut 20% of its workforce to save cash, a large infusion of money. By Matthew Herper On the eve of Halloween, the FDA weighs whether medicine should ever taste like candy Speakers debated the potential benefits and pitfalls of "candy-like" nonprescription drugs such as gummies, particularly for children. By Nicholas Florko Adobe STAT+ | Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease The FDA is seeking expert input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of off-target editing. By Megan Molteni and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser